AVEO Pharmaceuticals Inc. (NASDAQ:AVEO) saw a large growth in short interest in August. As of August 31st, there was short interest totalling 1,262,761 shares, a growth of 85.5% from the August 15th total of 680,697 shares. Based on an average daily trading volume, of 190,374 shares, the days-to-cover ratio is currently 6.6 days. Approximately 2.1% of the shares of the company are short sold.
Shares of AVEO Pharmaceuticals (NASDAQ:AVEO) opened at 0.8822 on Friday. The company’s market capitalization is $66.92 million. AVEO Pharmaceuticals has a 1-year low of $0.81 and a 1-year high of $1.47. The firm’s 50 day moving average price is $0.93 and its 200-day moving average price is $0.96.
Several large investors have recently modified their holdings of AVEO. Renaissance Technologies LLC boosted its stake in shares of AVEO Pharmaceuticals by 6.0% in the first quarter. Renaissance Technologies LLC now owns 2,094,900 shares of the biopharmaceutical company’s stock worth $1,927,000 after buying an additional 119,000 shares during the period. New Leaf Venture Partners L.L.C. bought a new stake in shares of AVEO Pharmaceuticals during the second quarter worth $2,490,000. Bridgeway Capital Management Inc. boosted its stake in shares of AVEO Pharmaceuticals by 63.7% in the second quarter. Bridgeway Capital Management Inc. now owns 514,051 shares of the biopharmaceutical company’s stock worth $494,000 after buying an additional 200,000 shares during the period. Spark Investment Management LLC bought a new stake in shares of AVEO Pharmaceuticals during the second quarter worth $281,000. Finally, Perceptive Advisors LLC bought a new stake in shares of AVEO Pharmaceuticals during the second quarter worth $2,987,000. Institutional investors and hedge funds own 39.10% of the company’s stock.
Several research firms recently commented on AVEO. FBR & Co reiterated an “outperform” rating and issued a $3.00 price objective on shares of AVEO Pharmaceuticals in a report on Thursday, July 7th. Piper Jaffray Cos. reiterated a “buy” rating on shares of AVEO Pharmaceuticals in a report on Thursday, June 16th. Finally, Zacks Investment Research upgraded AVEO Pharmaceuticals from a “hold” rating to a “buy” rating and set a $1.00 price objective for the company in a report on Tuesday, May 31st.
About AVEO Pharmaceuticals
AVEO Pharmaceuticals, Inc is a biopharmaceutical company. The Company’s platform delivers insights into cancer and related disease. The Company’s product candidates include Tivozanib, Ficlatuzumab, AV-203 and AV-380. Tivozanib is a selective long half-life vascular endothelial growth factor tyrosine kinase inhibitor (VEGF TKI) that inhibits over three VEGF receptors.
Receive News & Ratings for AVEO Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AVEO Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.